Archaeosomes display immunoadjuvant potential for a vaccine against Chagas disease

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 2, 2013, Pages 409-412

  Higa, Leticia H ^a   Corral, Ricardo S ^b   José Morilla, María ^a   Romero, Eder L ^a   Petray, Patricia B ^b  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^b HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

Author keywords

Archaeosomes; Immunology; Nanotechnology; Trypanosoma cruzi; Vaccine adjuvants

Indexed keywords

ARCHAEOSOME; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; PARASITE ANTIGEN; TRYPANOSOMA CRUZI ANTIGEN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; LIPOSOME; MEMBRANE LIPID; PROTOZOAL VACCINE; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CHAGAS DISEASE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; FEMALE; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PARASITEMIA; TH1 CELL; TRYPANOSOMA CRUZI; ANIMAL; ARGENTINA; BLOOD; C3H MOUSE; CHEMISTRY; DISEASE MODEL; HALORUBRUM; IMMUNOLOGY; ISOLATION AND PURIFICATION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ARGENTINA; CHAGAS DISEASE; DISEASE MODELS, ANIMAL; FEMALE; HALORUBRUM; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; LIPOSOMES; MEMBRANE LIPIDS; MICE, INBRED C3H; PARASITEMIA; PROTOZOAN VACCINES; SURVIVAL ANALYSIS; TH1 CELLS; TREATMENT OUTCOME;

EID: 84874731253     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22780     Document Type: Article

References (26)

1. The Special Programme for Research and Training in Tropical Diseases (TDR/WHO). Reporte sobre la Enfermedad de Chagas. Buenos Aires, Argentina. Guhl F, Ladzins-Helds JK, eds, 2007: 97.
2. Garg N, Bhatia V. Current status and future prospects for a vaccine against American trypanosomiasis. Expert Rev Vaccines 2005; 4:867-80; PMID:16372882; http://dx.doi.org/10.1586/14760584.4.6.867. (Pubitemid 43040907)
3. Quijano-Hernandez I, Dumonteil E. Advances and challenges towards a vaccine against Chagas disease. Hum Vaccin 2011; 7:1184-91; PMID:22048121; http://dx.doi.org/10.4161/hv.7.11.17016.
4. Sprott GD, Tolson DL, Patel GB. Archaeosomes as novel antigen delivery systems. FEMS Microbiol Lett 1997; 154:17-22; PMID:9297816; http://dx.doi.org/ 10.1016/S0378-1097(97)00294-2. (Pubitemid 27376731)
5. Krishnan L, Dicaire CJ, Patel GB, Sprott GD. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect Immun 2000; 68:54-63; PMID:10603368; http://dx.doi.org/10.1128/IAI.68.1.54-63.2000. (Pubitemid 30016677)
6. Li Z, Zhang L, Sun W, Ding Q, Hou Y, Xu Y. Archaeosomes with encapsulated antigens for oral vaccine delivery. Vaccine 2011; 29:5260-6; PMID:21609747; http://dx.doi.org/10.1016/j.vaccine.2011.05.015.
7. Sprott GD, Sad S, Fleming LP, Dicaire CJ, Patel GB, Krishnan L. Archaeosomes varying in lipid composition differ in receptor-mediated endocytosis and differentially adjuvant immune responses to entrapped antigen. Archaea 2003; 1:151-64; PMID:15803661; http://dx.doi.org/10.1155/2003/569283. (Pubitemid 38871643)
8. Krishnan L, Sad S, Patel GB, Sprott GD. The potent adjuvant activity of archaeosomes correlates to the recruitment and activation of macrophages and dendritic cells in vivo. J Immunol 2001 166:1885-93; PMID:11160236. (Pubitemid 32114675)
9. Nordly P, Korsholm KS, Pedersen EA, Khilji TS, Franzyk H, Jorgensen L, et al. Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo. Eur J Pharm Biopharm 2011; 77:89-98; PMID:20940050; http://dx.doi.org/10.1016/j.ejpb.2010.10.001.
10. Gonzalez RO, Higa LH, Cutrullis RA, Bilen M, Morelli I, Roncaglia DI, et al. Archaeosomes made of Halorubrum tebenquichense total polar lipids: a new source of adjuvancy. BMC Biotechnol 2009; 9:71; PMID:19678953; http://dx.doi.org/10.1186/1472-6750-9-71.
11. Conlan JW, Krishnan L, Willick GE, Patel GB, Sprott GD. Immunization of mice with lipopeptide antigens encapsulated in novel liposomes prepared from the polar lipids of various Archaeobacteria elicits rapid and prolonged specific protective immunity against infection with the facultative intracellular pathogen, Listeria monocytogenes. Vaccine 2001; 19:3509-17; PMID:11348718; http://dx.doi.org/10.1016/S0264-410X(01)00041-X. (Pubitemid 32710303)
12. Segura EL, Vazquez C, Bronzina A, Campos JM, Cerisola JA, Gonzalez Cappa SM. Antigens of the subcellular fraction of Trypanosoma cruzi. Part II: Flagellar and membrane fraction. J Protozool 1997
13. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54; PMID:942051; http://dx.doi.org/10.1016/0003- 2697(76)90527-3.
14. Stewart JCM. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980; 104:10-4; PMID:6892980; http://dx.doi.org/10.1016/0003-2697(80)90269-9.
15. Corral RS, Petray PB. CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi. Vaccine 2000; 19:234-42; PMID:10930678; http://dx.doi.org/10.1016/S0264-410X(00)00172-9. (Pubitemid 30621517)
16. Pizzi T. Prensa Medica Universitaria. Santiago de Chile, 1957, 38.
17. Hoft DF, Eickhoff CS. Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges. Infect Immun 2002; 70:6715-25; PMID:12438346; http://dx.doi.org/10.1128/IAI.70.12.6715-6725.2002. (Pubitemid 35387902)
18. Powell MR, Wassom DL. Host genetics and resistance to acute Trypanosoma cruzi infection in mice. I. Antibody isotype profiles. Parasite Immunol 1993; 15:215-21; PMID:8506117; http://dx.doi.org/10.1111/j.1365-3024.1993.tb00603.x. (Pubitemid 23132182)
19. Taliaferro WH, Pizzi T. Connective tissue reactions in normal and immunized mice to a reticulotropic strain of Trypanosoma cruzi. J Infect Dis 1955; 96:199-226; PMID:14392366; http://dx.doi.org/10.1093/infdis/96.3.199.
20. Krishnan L, Gurnani K, Dicaire CJ, van Faassen H, Zafer A, Kirschning CJ, et al. Rapid clonal expansion and prolonged maintenance of memory CD8+ T cells of the effector (CD44highCD62Llow) and central (CD44highCD62Lhigh) phenotype by an archaeosome adjuvant independent of TLR2. J Immunol 2007 178:2396-406; PMID:17277146. (Pubitemid 46233439)
21. de la Salle H, Mariotti S, Angenieux C, Gilleron M, Garcia-Alles L-F, Malm D, et al. Assistance of microbial glycolipid antigen processing by CD1e. Science 2005; 310:1321-4; PMID:16311334; http://dx.doi.org/10.1126/science. 1115301. (Pubitemid 41698862)
22. Krishnan L, Sad S, Patel GB, Sprott GD. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help. J Immunol 2000 165:5177-85; PMID:11046050.
23. Sprott GD, Dicaire CJ, Cote J-P, Whitfield DM. Adjuvant potential of archaeal synthetic glycolipid mimetics critically depends on the glyco head group structure. Glycobiology 2008; 18:559-65; PMID:18450974; http://dx.doi.org/10.1093/glycob/cwn038. (Pubitemid 351865836)
24. Higa LH, Schilrreff P, Perez AP, Iriarte MA, Roncaglia DI, Morilla MJ, et al. Ultradeformable archaeosomes as new topical adjuvants. Nanomedicine 2012 8:1319-28; PMID:22366598.
25. Tarleton RL Chagas disease: a role for autoimmunity? Trends Parasitol 2003 19 447-51 PMID:14519582 http://dx.doi.org/10.1016/j.pt.2003.08.008. (Pubitemid 38366141)
26. Esko JD, Doering TL, Raetz CRH. Eubacteria and Archaea. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, eds. Essentials of Glycobiology.2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 2009, Chapter 20.